Across TCGA pan-cancer cohorts, LINC01106 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated LINC01106 data layer compared with 23 for mass-spec protein.
The strongest signal is observed in skin cutaneous melanoma (SKCM), where higher LINC01106 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated LINC01106 expression acts as an unfavorable survival marker.
SKCM, CHOL, and ACC are the cancer types where LINC01106 Mutation most reproducibly stratifies survival.